<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582500</url>
  </required_header>
  <id_info>
    <org_study_id>2018-9791</org_study_id>
    <nct_id>NCT04582500</nct_id>
  </id_info>
  <brief_title>Virtual Colonoscopy Using Omnipaque as a Contrast Agent</brief_title>
  <official_title>Low-osmolar Contrast Tagging in Minimal Cathartic CT Colonography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CT colonography (CTC) is a validated screening exam for colorectal cancer. The diagnostic&#xD;
      accuracy of CTC depends on the quality of the bowel cleansing and contrast tagging of&#xD;
      residual stool and fluid. New bowel preparation media for CTC should be assessed for their&#xD;
      efficacy and for patient satisfaction. Iohexol is currently approved by the FDA for oral use&#xD;
      for imaging of the gastrointestinal tract. A potential advantage of using iohexol for CTC is&#xD;
      that low-and iso-osmolar oral contrast agents have fewer risks than hyperosmolar contrast&#xD;
      agents, which make them ideal for use in all patients, especially those who are frail and/or&#xD;
      have multiple co-morbidities. For example, hyperosmolar contrast agents that are accidentally&#xD;
      aspirated into the lungs during ingestion may result in life-threatening acute pulmonary&#xD;
      edema and severe chemical pneumonitis, which is not the case for low- and iso-osmolar&#xD;
      contrast agents. It may even be safer to use low- or iso-osmolar contrast agents for patients&#xD;
      undergoing CTC on the same day as their incomplete colonoscopy, since they are at risk for&#xD;
      aspiration from being sedated for their colonoscopy. Additionally, unlike hyperosmolar&#xD;
      contrast agents, low- and iso-osmolar contrast agents do not cause sudden and massive fluid&#xD;
      shifts, thus eliminating the risk of dangerous electrolyte imbalances.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer is the third most common cancer and the second leading cause of&#xD;
      cancer-related mortality in the United States when both sexes are combined. Given that the&#xD;
      time interval between the appearance of a pre-malignant adenoma and its progression to&#xD;
      invasive carcinoma is approximately 5.5 years for polyps &gt;10 mm and 10-15 years for smaller&#xD;
      polyps, colorectal cancer is an ideal disease for screening because there is sufficient time&#xD;
      to detect and remove pre-malignant adenomas. However, even though screening has been shown to&#xD;
      decrease colorectal cancer mortality, only about 60% of people over the age of 50 have had&#xD;
      the recommended screening tests.&#xD;
&#xD;
      First introduced in 1994, computed tomography colonography (CTC) is a validated colorectal&#xD;
      cancer screening exam by the American Cancer Society. It is a low-radiation dose CT scan of&#xD;
      the colon that is performed after bowel preparation and gas insufflation of the colon. CTC&#xD;
      has several advantages over optical colonoscopy including less invasiveness, no need for&#xD;
      sedation, improved patient comfort, and the ability to identify extracolonic findings. The&#xD;
      performance of CTC for polyp detection compares favorably to that of optical colonoscopy and&#xD;
      CTC is rapidly gaining acceptance as a screening and diagnostic technique.&#xD;
&#xD;
      For accurate diagnosis in CTC, the colon must be adequately cleansed and any residual stool&#xD;
      and fluid must be tagged so that they do not obscure polyps or masses. Patients often find&#xD;
      bowel preparation to be the most onerous part of the screening process because it is&#xD;
      inconvenient and uncomfortable. Many bowel preparations for CTC and optical colonoscopy&#xD;
      require ingestion of large volumes of laxative solutions that can lead to nausea, abdominal&#xD;
      pain and diarrhea. Additionally, for CTC, currently the most widely used tagging agents are&#xD;
      hyperosmolar iodinated and barium based agents such as diatrizoate meglumine and diatrizoate&#xD;
      sodium solution (Gastrografin; Bracco Diagnostics, Monroe Township, NJ), a hyperosmolar ionic&#xD;
      iodinated contrast agent. These hyperosmolar agents can also lead to nausea, abdominal pain&#xD;
      and diarrhea, and can even result in dangerous electrolyte balances from rapid fluid shifts.&#xD;
      Changing the current bowel preparation regimen to improve patient comfort, convenience, and&#xD;
      safety would most likely increase patient compliance with CTC.&#xD;
&#xD;
      Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated&#xD;
      contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT&#xD;
      scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better&#xD;
      tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium&#xD;
      based contrast agents.&#xD;
&#xD;
      Study Hypotheses&#xD;
&#xD;
        1. Oral iohexol in conjunction with a minimally cathartic agent results in adequate bowel&#xD;
           preparation for CTC.&#xD;
&#xD;
        2. Oral iohexol provides effective tagging of residual stool and fluid in standard&#xD;
           screening and diagnostic CTC and same-day CTC following incomplete optical colonoscopy.&#xD;
&#xD;
        3. Oral iohexol is well tolerated by patients in terms of taste, ease of preparation, and&#xD;
           side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>adequate bowel preparation</measure>
    <time_frame>Within 3 business days of completing CTC</time_frame>
    <description>Two experienced board-certified abdominal imaging radiologists trained in reading CTC will assess percent bowel preparation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of residual fluid and stool</measure>
    <time_frame>Within 3 business days of completing CTC</time_frame>
    <description>Two experienced board-certified abdominal imaging radiologists trained in reading CTC will assess residual fluid in each of the six segments of the colon (cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum)- Each segment will be scored as - 1 - none, 2 - &lt;25%, 3 - 25-50%, 4: 50-75%, 5: &gt;75%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of residual fluid and stool</measure>
    <time_frame>Within 3 business days of completing CTC</time_frame>
    <description>Two experienced board-certified abdominal imaging radiologists trained in reading CTC will assess residual fluid in each of the six segments of the colon (cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum)- Each segment will be scored as - 1 - none, 2 - &lt;25%, 3 - 25-50%, 4: 50-75%, 5: &gt;75%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of colonic bubbles</measure>
    <time_frame>Within 3 business days of completing CTC</time_frame>
    <description>Two experienced board-certified abdominal imaging radiologists trained in reading CTC will assess residual fluid in each of the six segments of the colon (cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum)- Each segment will be scored as - 1 - none, 2 - &lt;25%, 3 - 25-50%, 4: 50-75%, 5: &gt;75%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attenuation of tagged fluid</measure>
    <time_frame>Within 3 business days of completing CTC</time_frame>
    <description>Two experienced board-certified abdominal imaging radiologists trained in reading CTC will assess residual fluid in each of the six segments of the colon (cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum) It will be recorded in Hounsfield units from ROI of fluid in each segment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>immediately after CTC</time_frame>
    <description>Patient satisfaction with Omnipaque 350 as part of their bowel preparation regimen will be assessed with Likert scales in a questionnaire that patient will be asked to fill out after CTC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessing Workflow of incomplete colonoscopies</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>A subset analysis on the workflow of incomplete colonoscopies will also be performed. Specifically those patients who have an incomplete colonoscopy and have a CTC the same day with the Omnipaque regimen and those patients who choose to reattempt or forgo Colorectal cancer screening until a later date.&#xD;
The time and resources between those patients who have CTC on the same-day with the Omnipaque regimen after incomplete colonoscopy and the other subset will be compared and determination of the effectiveness of both workflows will be made. This will be used to gauge the productivity for the site.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>patients undergoing CTC receiving iohexol</arm_group_label>
    <description>Patients will be recruited from a pool scheduled to undergo screening or diagnostic CTC for clinical purposes. They will be given 50 ml of Iohexol as a oral contrast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium based contrast agents.</description>
    <arm_group_label>patients undergoing CTC receiving iohexol</arm_group_label>
    <other_name>OMNIPAQUE</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from a pool scheduled to undergo screening or diagnostic CTC for&#xD;
        clinical purposes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥18 years&#xD;
&#xD;
          -  able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypersensitivity to iodine-containing compounds,&#xD;
&#xD;
          -  pregnant or lactating,&#xD;
&#xD;
          -  diuretic therapy, and&#xD;
&#xD;
          -  enrollment in other clinical research trials involving investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judy Yee, MD, FACR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parina Shah, MS, MHA</last_name>
    <phone>718-920-6267</phone>
    <email>parishah@montefiore.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parina Shah, MS, MHA</last_name>
      <phone>718-920-6267</phone>
      <email>parishah@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Judy Yee, MD, FACR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.</citation>
    <PMID>25559415</PMID>
  </reference>
  <reference>
    <citation>Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975 Dec;36(6):2251-70.</citation>
    <PMID>1203876</PMID>
  </reference>
  <reference>
    <citation>Smith RA, Manassaram-Baptiste D, Brooks D, Doroshenk M, Fedewa S, Saslow D, Brawley OW, Wender R. Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015 Jan-Feb;65(1):30-54. doi: 10.3322/caac.21261. Epub 2015 Jan 8. Review.</citation>
    <PMID>25581023</PMID>
  </reference>
  <reference>
    <citation>American Cancer Society. Colorectal Cancer Facts &amp; Figures 2014-2016. Atlanta: American Cancer Society, 2014</citation>
  </reference>
  <reference>
    <citation>Thomeer M, Bielen D, Vanbeckevoort D, Dymarkowski S, Gevers A, Rutgeerts P, Hiele M, Van Cutsem E, Marchal G. Patient acceptance for CT colonography: what is the real issue? Eur Radiol. 2002 Jun;12(6):1410-5. Epub 2002 Apr 24.</citation>
    <PMID>12042947</PMID>
  </reference>
  <reference>
    <citation>Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash C, Giardiello FM, Glick S, Levin TR, Pickhardt P, Rex DK, Thorson A, Winawer SJ; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008 May-Jun;58(3):130-60. doi: 10.3322/CA.2007.0018. Epub 2008 Mar 5.</citation>
    <PMID>18322143</PMID>
  </reference>
  <reference>
    <citation>Lefere PA, Gryspeerdt SS, Dewyspelaere J, Baekelandt M, Van Holsbeeck BG. Dietary fecal tagging as a cleansing method before CT colonography: initial results polyp detection and patient acceptance. Radiology. 2002 Aug;224(2):393-403.</citation>
    <PMID>12147834</PMID>
  </reference>
  <reference>
    <citation>Iannaccone R, Laghi A, Catalano C, Mangiapane F, Lamazza A, Schillaci A, Sinibaldi G, Murakami T, Sammartino P, Hori M, Piacentini F, Nofroni I, Stipa V, Passariello R. Computed tomographic colonography without cathartic preparation for the detection of colorectal polyps. Gastroenterology. 2004 Nov;127(5):1300-11.</citation>
    <PMID>15520999</PMID>
  </reference>
  <reference>
    <citation>Laghi A, Iannaccone R, Carbone I, Catalano C, Di Giulio E, Schillaci A, Passariello R. Detection of colorectal lesions with virtual computed tomographic colonography. Am J Surg. 2002 Feb;183(2):124-31.</citation>
    <PMID>11918874</PMID>
  </reference>
  <reference>
    <citation>Laghi A, Iannaccone R, Carbone I, Catalano C, Panebianco V, Di Giulio E, Schillaci A, Passariello R. Computed tomographic colonography (virtual colonoscopy): blinded prospective comparison with conventional colonoscopy for the detection of colorectal neoplasia. Endoscopy. 2002 Jun;34(6):441-6.</citation>
    <PMID>12048624</PMID>
  </reference>
  <reference>
    <citation>Macari M, Bini EJ, Jacobs SL, Lui YW, Laks S, Milano A, Babb J. Significance of missed polyps at CT colonography. AJR Am J Roentgenol. 2004 Jul;183(1):127-34.</citation>
    <PMID>15208126</PMID>
  </reference>
  <reference>
    <citation>Macari M, Bini EJ, Xue X, Milano A, Katz SS, Resnick D, Chandarana H, Krinsky G, Klingenbeck K, Marshall CH, Megibow AJ. Colorectal neoplasms: prospective comparison of thin-section low-dose multi-detector row CT colonography and conventional colonoscopy for detection. Radiology. 2002 Aug;224(2):383-92.</citation>
    <PMID>12147833</PMID>
  </reference>
  <reference>
    <citation>Munikrishnan V, Gillams AR, Lees WR, Vaizey CJ, Boulos PB. Prospective study comparing multislice CT colonography with colonoscopy in the detection of colorectal cancer and polyps. Dis Colon Rectum. 2003 Oct;46(10):1384-90.</citation>
    <PMID>14530680</PMID>
  </reference>
  <reference>
    <citation>Pickhardt PJ, Choi JR, Hwang I, Butler JA, Puckett ML, Hildebrandt HA, Wong RK, Nugent PA, Mysliwiec PA, Schindler WR. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med. 2003 Dec 4;349(23):2191-200. Epub 2003 Dec 1.</citation>
    <PMID>14657426</PMID>
  </reference>
  <reference>
    <citation>Pickhardt PJ, Taylor AJ, Kim DH, Reichelderfer M, Gopal DV, Pfau PR. Screening for colorectal neoplasia with CT colonography: initial experience from the 1st year of coverage by third-party payers. Radiology. 2006 Nov;241(2):417-25. Epub 2006 Sep 18.</citation>
    <PMID>16982816</PMID>
  </reference>
  <reference>
    <citation>Bayer. Bayer's product. Available via http://www.bayerresources.com.au/resources /uploads/PI/file9348.pdf. Accessed July 15, 2015.</citation>
  </reference>
  <reference>
    <citation>U.S. Food and Drug Administration. Omnipaque (iohexol) injection. Available via http:// www.accessdata.fda.gov/drugsatfda_docs/label/2015/018956s095,020608s031lbl.pdf. Accessed July 16, 2015</citation>
  </reference>
  <reference>
    <citation>Horton KM, Fishman EK, Gayler B. The use of iohexol as oral contrast for computed tomography of the abdomen and pelvis. J Comput Assist Tomogr. 2008 Mar-Apr;32(2):207-9. doi: 10.1097/RCT.0b013e3180674e44.</citation>
    <PMID>18379303</PMID>
  </reference>
  <reference>
    <citation>McNamara MM, Lockhart ME, Fineberg NS, Berland LL. Oral contrast media for body CT: Comparison of diatrizoate sodium and iohexol for patient acceptance and bowel opacification. AJR Am J Roentgenol. 2010 Nov;195(5):1137-41. doi: 10.2214/AJR.09.3968.</citation>
    <PMID>20966319</PMID>
  </reference>
  <reference>
    <citation>Peterson CM, Lin M, Pilgram T, Heiken JP. Prospective randomized trial of iohexol 350 versus meglumine sodium diatrizoate as an oral contrast agent for abdominopelvic computed tomography. J Comput Assist Tomogr. 2011 Mar-Apr;35(2):202-5. doi: 10.1097/RCT.0b013e3182058e76.</citation>
    <PMID>21412090</PMID>
  </reference>
  <reference>
    <citation>Nagata K, Singh AK, Sangwaiya MJ, Näppi J, Zalis ME, Cai W, Yoshida H. Comparative evaluation of the fecal-tagging quality in CT colonography: barium vs. iodinated oral contrast agent. Acad Radiol. 2009 Nov;16(11):1393-9. doi: 10.1016/j.acra.2009.05.003. Epub 2009 Jul 10.</citation>
    <PMID>19596591</PMID>
  </reference>
  <reference>
    <citation>Kim B, Park SH, Hong GS, Lee JH, Lee JS, Kim HJ, Kim AY, Ha HK. Iohexol versus diatrizoate for fecal/fluid tagging during CT colonography performed with cathartic preparation: comparison of examination quality. Eur Radiol. 2015 Jun;25(6):1561-9. doi: 10.1007/s00330-014-3568-0. Epub 2015 Jan 11.</citation>
    <PMID>25576229</PMID>
  </reference>
  <reference>
    <citation>Hong GS, Park SH, Kim B, Lee JH, Kim JC, Yu CS, Baek S, Lee JS, Kim HJ. Simethicone to prevent colonic bubbles during CT colonography performed with polyethylene glycol lavage and iohexol tagging: a randomized clinical trial. AJR Am J Roentgenol. 2015 Apr;204(4):W429-38. doi: 10.2214/AJR.14.13024.</citation>
    <PMID>25794092</PMID>
  </reference>
  <reference>
    <citation>Zalis ME, Perumpillichira JJ, Magee C, Kohlberg G, Hahn PF. Tagging-based, electronically cleansed CT colonography: evaluation of patient comfort and image readability. Radiology. 2006 Apr;239(1):149-59. Erratum in: Radiology. 2006 Jul;240(1):304.</citation>
    <PMID>16567485</PMID>
  </reference>
  <reference>
    <citation>Cai W, Yoshida H, Zalis ME, Näppi JJ, Harris GJ. Informatics in radiology: Electronic cleansing for noncathartic CT colonography: a structure-analysis scheme. Radiographics. 2010 May;30(3):585-602. doi: 10.1148/rg.303095154. Epub 2010 Mar 10.</citation>
    <PMID>20219839</PMID>
  </reference>
  <reference>
    <citation>Fletcher JG, Silva AC, Fidler JL, Cernigliaro JG, Manduca A, Limburg PJ, Wilson LA, Engelby TA, Spencer G, Harmsen WS, Mandrekar J, Johnson CD. Noncathartic CT colonography: Image quality assessment and performance and in a screening cohort. AJR Am J Roentgenol. 2013 Oct;201(4):787-94. doi: 10.2214/AJR.12.9225.</citation>
    <PMID>24059367</PMID>
  </reference>
  <reference>
    <citation>Pollentine A, Ngan-Soo E, McCoubrie P. Acceptability of oral iodinated contrast media: a head-to-head comparison of four media. Br J Radiol. 2013 May;86(1025):20120636. doi: 10.1259/bjr.20120636.</citation>
    <PMID>23564884</PMID>
  </reference>
  <reference>
    <citation>Gryspeerdt S, Lefere P, Herman M, Deman R, Rutgeerts L, Ghillebert G, Baert F, Baekelandt M, Van Holsbeeck B. CT colonography with fecal tagging after incomplete colonoscopy. Eur Radiol. 2005 Jun;15(6):1192-202. Epub 2005 Feb 9.</citation>
    <PMID>15702335</PMID>
  </reference>
  <reference>
    <citation>Bielen D, Thomeer M, Vanbeckevoort D, Kiss G, Maes F, Marchal G, Rutgeerts P. Dry preparation for virtual CT colonography with fecal tagging using water-soluble contrast medium: initial results. Eur Radiol. 2003 Mar;13(3):453-8. Epub 2002 Nov 14.</citation>
    <PMID>12594546</PMID>
  </reference>
  <reference>
    <citation>Callstrom MR, Johnson CD, Fletcher JG, Reed JE, Ahlquist DA, Harmsen WS, Tait K, Wilson LA, Corcoran KE. CT colonography without cathartic preparation: feasibility study. Radiology. 2001 Jun;219(3):693-8.</citation>
    <PMID>11376256</PMID>
  </reference>
  <reference>
    <citation>Lefere P, Gryspeerdt S, Marrannes J, Baekelandt M, Van Holsbeeck B. CT colonography after fecal tagging with a reduced cathartic cleansing and a reduced volume of barium. AJR Am J Roentgenol. 2005 Jun;184(6):1836-42.</citation>
    <PMID>15908539</PMID>
  </reference>
  <reference>
    <citation>Thomeer M, Carbone I, Bosmans H, Kiss G, Bielen D, Vanbeckevoort D, Van Cutsem E, Rutgeerts P, Marchal G. Stool tagging applied in thin-slice multidetector computed tomography colonography. J Comput Assist Tomogr. 2003 Mar-Apr;27(2):132-9.</citation>
    <PMID>12703001</PMID>
  </reference>
  <reference>
    <citation>Zalis ME, Perumpillichira J, Del Frate C, Hahn PF. CT colonography: digital subtraction bowel cleansing with mucosal reconstruction initial observations. Radiology. 2003 Mar;226(3):911-7. Epub 2003 Jan 24.</citation>
    <PMID>12601218</PMID>
  </reference>
  <reference>
    <citation>Iafrate F, Hassan C, Zullo A, Stagnitti A, Ferrari R, Spagnuolo A, Laghi A. CT colonography with reduced bowel preparation after incomplete colonoscopy in the elderly. Eur Radiol. 2008 Jul;18(7):1385-95. doi: 10.1007/s00330-008-0892-2. Epub 2008 Mar 20.</citation>
    <PMID>18351357</PMID>
  </reference>
  <reference>
    <citation>Park SH, Yee J, Kim SH, Kim YH. Fundamental elements for successful performance of CT colonography (virtual colonoscopy). Korean J Radiol. 2007 Jul-Aug;8(4):264-75. Review.</citation>
    <PMID>17673837</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

